CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
Identifieur interne : 000388 ( PubMed/Corpus ); précédent : 000387; suivant : 000389CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
Auteurs : Awewura Kwara ; Margaret Lartey ; Kwamena W C. Sagoe ; Ernest Kenu ; Michael H. CourtSource :
- AIDS (London, England) [ 1473-5571 ] ; 2009.
English descriptors
- KwdEn :
- Adult, African Continental Ancestry Group (genetics), Aryl Hydrocarbon Hydroxylases (genetics), Benzoxazines (blood), Benzoxazines (pharmacokinetics), Cytochrome P-450 CYP2A6, Cytochrome P-450 CYP2B6, Dose-Response Relationship, Drug, Female, Genotype, Ghana, Glucuronosyltransferase (genetics), HIV Infections (blood), HIV Infections (drug therapy), HIV Infections (genetics), Humans, Male, Oxidoreductases, N-Demethylating (genetics), Polymorphism, Single Nucleotide, Predictive Value of Tests, Reverse Transcriptase Inhibitors (blood), Reverse Transcriptase Inhibitors (pharmacokinetics).
- MESH :
- chemical , blood : Benzoxazines, Reverse Transcriptase Inhibitors.
- chemical , genetics : Aryl Hydrocarbon Hydroxylases, Glucuronosyltransferase, Oxidoreductases, N-Demethylating.
- blood : HIV Infections.
- drug therapy : HIV Infections.
- genetics : African Continental Ancestry Group, HIV Infections.
- chemical , pharmacokinetics : Benzoxazines, Reverse Transcriptase Inhibitors.
- Adult, Cytochrome P-450 CYP2A6, Cytochrome P-450 CYP2B6, Dose-Response Relationship, Drug, Female, Genotype, Ghana, Humans, Male, Polymorphism, Single Nucleotide, Predictive Value of Tests.
Abstract
UDP-glucuronosyltransferase (UGT) 2B7 was recently identified as the main enzyme mediating efavirenz N-glucuronidation. In this study, we determined whether selected UGT2B7 polymorphisms could be used to enhance the prediction of efavirenz plasma concentrations from CYP2B6 and CYP2A6 genotypes.
DOI: 10.1097/QAD.0b013e3283319908
PubMed: 19779319
Links to Exploration step
pubmed:19779319Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.</title><author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name><affiliation><nlm:affiliation>Warren Alpert Medical School of Brown University, Rhode Island, USA. akwara@lifespan.org</nlm:affiliation></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name></author><author><name sortKey="Sagoe, Kwamena W C" sort="Sagoe, Kwamena W C" uniqKey="Sagoe K" first="Kwamena W C" last="Sagoe">Kwamena W C. Sagoe</name></author><author><name sortKey="Kenu, Ernest" sort="Kenu, Ernest" uniqKey="Kenu E" first="Ernest" last="Kenu">Ernest Kenu</name></author><author><name sortKey="Court, Michael H" sort="Court, Michael H" uniqKey="Court M" first="Michael H" last="Court">Michael H. Court</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19779319</idno><idno type="pmid">19779319</idno><idno type="doi">10.1097/QAD.0b013e3283319908</idno><idno type="wicri:Area/PubMed/Corpus">000388</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000388</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.</title><author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name><affiliation><nlm:affiliation>Warren Alpert Medical School of Brown University, Rhode Island, USA. akwara@lifespan.org</nlm:affiliation></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name></author><author><name sortKey="Sagoe, Kwamena W C" sort="Sagoe, Kwamena W C" uniqKey="Sagoe K" first="Kwamena W C" last="Sagoe">Kwamena W C. Sagoe</name></author><author><name sortKey="Kenu, Ernest" sort="Kenu, Ernest" uniqKey="Kenu E" first="Ernest" last="Kenu">Ernest Kenu</name></author><author><name sortKey="Court, Michael H" sort="Court, Michael H" uniqKey="Court M" first="Michael H" last="Court">Michael H. Court</name></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="eISSN">1473-5571</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>African Continental Ancestry Group (genetics)</term><term>Aryl Hydrocarbon Hydroxylases (genetics)</term><term>Benzoxazines (blood)</term><term>Benzoxazines (pharmacokinetics)</term><term>Cytochrome P-450 CYP2A6</term><term>Cytochrome P-450 CYP2B6</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Genotype</term><term>Ghana</term><term>Glucuronosyltransferase (genetics)</term><term>HIV Infections (blood)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (genetics)</term><term>Humans</term><term>Male</term><term>Oxidoreductases, N-Demethylating (genetics)</term><term>Polymorphism, Single Nucleotide</term><term>Predictive Value of Tests</term><term>Reverse Transcriptase Inhibitors (blood)</term><term>Reverse Transcriptase Inhibitors (pharmacokinetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Benzoxazines</term><term>Reverse Transcriptase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Aryl Hydrocarbon Hydroxylases</term><term>Glucuronosyltransferase</term><term>Oxidoreductases, N-Demethylating</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>African Continental Ancestry Group</term><term>HIV Infections</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Benzoxazines</term><term>Reverse Transcriptase Inhibitors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cytochrome P-450 CYP2A6</term><term>Cytochrome P-450 CYP2B6</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Genotype</term><term>Ghana</term><term>Humans</term><term>Male</term><term>Polymorphism, Single Nucleotide</term><term>Predictive Value of Tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">UDP-glucuronosyltransferase (UGT) 2B7 was recently identified as the main enzyme mediating efavirenz N-glucuronidation. In this study, we determined whether selected UGT2B7 polymorphisms could be used to enhance the prediction of efavirenz plasma concentrations from CYP2B6 and CYP2A6 genotypes.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19779319</PMID><DateCreated><Year>2009</Year><Month>10</Month><Day>13</Day></DateCreated><DateCompleted><Year>2011</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>16</Issue><PubDate><Year>2009</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>AIDS (London, England)</Title><ISOAbbreviation>AIDS</ISOAbbreviation></Journal><ArticleTitle>CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.</ArticleTitle><Pagination><MedlinePgn>2101-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0b013e3283319908</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">UDP-glucuronosyltransferase (UGT) 2B7 was recently identified as the main enzyme mediating efavirenz N-glucuronidation. In this study, we determined whether selected UGT2B7 polymorphisms could be used to enhance the prediction of efavirenz plasma concentrations from CYP2B6 and CYP2A6 genotypes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Mid-dose efavirenz plasma concentrations were determined in 94 HIV-infected Ghanaian patients at 2-8 weeks of antiretroviral therapy. CYP2B6 and CYP2A6 genotypes had been previously reported. UGT2B7 exon 2 single-nucleotide polymorphisms (SNPs) c.735A>G (UGT2B7*1c; rs28365062) and c.802C>T (H268Y; UGT2B7*2; rs7439366) were determined by direct sequencing with UGT2B7*1a defined as the reference allele. Relationships between efavirenz plasma concentrations, demographic variables and genotypes were evaluated by univariate and multivariate statistical approaches.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean (+/-SD) mid-dose efavirenz plasma concentration was 3218 (+/-3905) ng/ml with coefficient of variation of 121%. Independent predictors of efavirenz concentration included CYP2B6 c.516TT genotype (4030 ng/ml increase; 95% confidence interval 2882-5505 ng/ml, P < 0.001), UGT2B7*1a carrier status (475 ng/ml increase; 95% confidence interval 138-899 ng/ml, P = 0.004) and CYP2A6*9 and/or *17 carrier status (372 ng/ml increase; 95% confidence interval 74-742 ng/ml, P = 0.013). Overall, CYP2B6 c.516TT genotype, UGT2B7*1a carrier status and CYP2A6*9 or *17 carrier status accounted for 45.2, 10.1 and 8.6% of the total variance, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings demonstrate independent effects of CYP2A6 and UGT2B7 genetic variation on efavirenz disposition beyond that of the CYP2B6 polymorphisms. The development and testing of a pharmacogenetic algorithm for estimating the appropriate dose of efavirenz should incorporate genotypic data from both the oxidative and glucuronidation pathways.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwara</LastName><ForeName>Awewura</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University, Rhode Island, USA. akwara@lifespan.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lartey</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sagoe</LastName><ForeName>Kwamena W C</ForeName><Initials>KW</Initials></Author><Author ValidYN="Y"><LastName>Kenu</LastName><ForeName>Ernest</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Court</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30AI042853</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01GM061834</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI071760</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM061834</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI042853</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI071760-04</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI050410</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS</MedlineTA><NlmUniqueID>8710219</NlmUniqueID><ISSNLinking>0269-9370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048588">Benzoxazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="D001189">Aryl Hydrocarbon Hydroxylases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="C585710">CYP2A6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="C585599">CYP2B6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="D065637">Cytochrome P-450 CYP2A6</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber><NameOfSubstance UI="D065702">Cytochrome P-450 CYP2B6</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.5.-</RegistryNumber><NameOfSubstance UI="D010089">Oxidoreductases, N-Demethylating</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.-</RegistryNumber><NameOfSubstance UI="C491474">UGT2B7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.17</RegistryNumber><NameOfSubstance UI="D014453">Glucuronosyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>JE6H2O27P8</RegistryNumber><NameOfSubstance UI="C098320">efavirenz</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Drug Metab Dispos. 1999 Nov;27(11):1319-33</RefSource><PMID Version="1">10534318</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2001 Jan 5;15(1):71-5</RefSource><PMID Version="1">11192870</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenetics. 2001 Jul;11(5):399-415</RefSource><PMID Version="1">11470993</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Med Res. 2002 Jul 24;7(7):309-14</RefSource><PMID Version="1">12176680</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacol Ther. 2003 Jan;73(1):20-30</RefSource><PMID Version="1">12545140</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenomics J. 2003;3(1):17-26</RefSource><PMID Version="1">12629580</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2003 Jul;306(1):287-300</RefSource><PMID Version="1">12676886</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Metab Dispos. 2003 Sep;31(9):1125-33</RefSource><PMID Version="1">12920168</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ther Drug Monit. 2004 Jun;26(3):267-70</RefSource><PMID Version="1">15167626</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 2004 Jul 9;319(4):1322-6</RefSource><PMID Version="1">15194512</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Metab Dispos. 2004 Sep;32(9):1048-54</RefSource><PMID Version="1">15319348</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2004 Dec 3;18(18):2391-400</RefSource><PMID Version="1">15622315</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenet Genomics. 2005 Jan;15(1):1-5</RefSource><PMID Version="1">15864119</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2005 Jul;6 Suppl 2:62-83</RefSource><PMID Version="1">16011537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2006 Mar;22(3):232-9</RefSource><PMID Version="1">16545009</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ther Drug Monit. 2006 Aug;28(4):517-25</RefSource><PMID Version="1">16885719</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2006 Dec;58(6):1299-302</RefSource><PMID Version="1">17032686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacol Ther. 2007 Apr;81(4):557-66</RefSource><PMID Version="1">17235330</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr HIV Res. 2007 May;5(3):349-53</RefSource><PMID Version="1">17504177</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenomics. 2007 Jun;8(6):547-58</RefSource><PMID Version="1">17559344</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2007 Nov 1;45(9):1230-7</RefSource><PMID Version="1">17918089</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Pharmacol Toxicol. 2008;48:227-56</RefSource><PMID Version="1">17883329</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Pharmacol. 2008 Apr;64(4):357-65</RefSource><PMID Version="1">18057928</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2008 Aug 6;300(5):555-70</RefSource><PMID Version="1">18677028</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Pharmacol. 2008 Sep;48(9):1032-40</RefSource><PMID Version="1">18728241</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Nov 30;22(18):2549-51</RefSource><PMID Version="1">19005282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Jan 28;23(3):433-4</RefSource><PMID Version="1">19188761</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2009 Mar;53(3):863-8</RefSource><PMID Version="1">19124658</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Mar 27;23(6):742-4</RefSource><PMID Version="1">19279450</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenet Genomics. 2009 Apr;19(4):300-9</RefSource><PMID Version="1">19238117</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 2009 Apr;67(4):427-36</RefSource><PMID Version="1">19371316</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacol Ther. 2009 May;85(5):485-94</RefSource><PMID Version="1">19225447</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Metab Dispos. 2009 Sep;37(9):1793-6</RefSource><PMID Version="1">19487252</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Pharmacol. 2009 Sep;49(9):1079-90</RefSource><PMID Version="1">19628728</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="N">African Continental Ancestry Group</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001189" MajorTopicYN="N">Aryl Hydrocarbon Hydroxylases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048588" MajorTopicYN="N">Benzoxazines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065637" MajorTopicYN="N">Cytochrome P-450 CYP2A6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065702" MajorTopicYN="N">Cytochrome P-450 CYP2B6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N">Ghana</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014453" MajorTopicYN="N">Glucuronosyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010089" MajorTopicYN="N">Oxidoreductases, N-Demethylating</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018894" MajorTopicYN="N">Reverse Transcriptase Inhibitors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS202920</OtherID><OtherID Source="NLM">PMC2875867</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19779319</ArticleId><ArticleId IdType="doi">10.1097/QAD.0b013e3283319908</ArticleId><ArticleId IdType="pmc">PMC2875867</ArticleId><ArticleId IdType="mid">NIHMS202920</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000388 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000388 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:19779319
|texte= CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19779319" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |